Navigation Links
Acella Pharmaceuticals Announces a New Addition to the Commercial Team
Date:5/1/2012

ATLANTA, May 1, 2012 /PRNewswire/ -- Atlanta-based Acella Pharmaceuticals, LLC, announces the addition of Tom Larkin as Vice President of Sales and Marketing of their commercial team. Tom will lead the commercial sales and marketing organization for Acella's product line.   

Tom is a highly accomplished, entrepreneurial Sales & Marketing Executive, bringing more than 11 years of industry experience, including sales, marketing and managed-care experience, to Acella. He has built and led commercial sales teams at The Harvard Drug Group that delivered significant increases in revenue under his leadership.  In addition, his commercial team managed a product portfolio of more than 800 products under the Major Pharmaceuticals label. Tom holds a Bachelor of Arts Degree in Finance from Florida Atlantic University.

"We are extremely excited to add a person of Tom's talent to our commercial organization," said Mark Pugh, CEO of ACELLA.  "He will be of incredible value to the company as we continue to execute on delivering high-quality, affordable products to market."

About Acella Pharmaceuticals, LLC.

Acella develops, markets, sells and distributes a broad portfolio of non-branded pharmaceutical and other products in the areas of Dermatology, Women's Health, Pediatrics and other applications. Acella specializes in identifying and bringing to market quality, affordable products to customers and patients. For additional information please contact Acella at 678-325-5189.


'/>"/>
SOURCE Acella Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Acella Pharmaceuticals, LLC, Files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration
2. Acella Pharmaceuticals, LLC Announces Its Acquisition of the PRENATE® Family of Trademarks and Associated Intellectual Property
3. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
5. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
6. Avanir Pharmaceuticals To Present at Three Conferences In May
7. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
8. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... ... Cellairis is a worldwide mobile device and computer repair franchise that is known ... Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up for business ... customers. While customers do their shopping, Cellairis can accomplish a number of mobile device ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, ... safely ride all types of amusement park rides. , The patent-pending SAFETY STRAP FOR ... easy to use and could be set up in a matter of minutes, or ...
(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
Breaking Medicine News(10 mins):